NCT06373133View on ClinicalTrials.gov

SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Colorectal Cancer
Interventions
DRUG

SHR-8068

1mg/kg，ivgtt, d1, q6w or 4mg/kg，ivgtt, d1, q12w

DRUG

Adebrelimab

1200mg, ivgtt, d1, q3w

DRUG

BP102

7.5mg/kg, ivgtt, d1, q3w

All Listed Sponsors
lead

West China Hospital

OTHER

NCT06373133 - SHR-8068 Combined With Adbelizumab and BP102 in the Treatment of Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter